Therapeutic effect of gefitinib on non small cell lung carcinoma and its influence on serum VEGF, MMP-9 and TIMP-1
QIAN Haihong
Abstract：Objective To observe the changes of expression levels of serum vascular endothelial growth factor (VEGF),matrix metalloproteinase-9(MMP-9) and tissue inhibitors of metalloproteinase (TIMP)-1 before and after treatment of non small cell lung carcinoma ( NSCLC) by gefitinib in order to explore the correlation between the changes and therapeutic effect.Methods The serum levels of VEGF ,MMP-9 and TIMP-1were detected by ELISA in 48 patients with NSCLC before and after treatment by gefitinib ,and the therapeutic effects were evaluated according to RECIST evaluation criterion.Results There were no significant differences in the serum levels of VEGF before and after treatment by gefitinib (P >0.05).However after treatment the serum levels of MMP-9 and TIMP-1 were obviously decreased ,as compared with those before treatment ( P<0.05).There were no obvious changes in serum levels of VEGF in valid group before and after treatment by gefitinib ( P >0.05),but after treatment the serum levels of MMP-9 and TIMP-1 were significantly decreased in valid group ,as compared with those before treatment( P <0.05).Furthermore there were no obvious changes in serum levels of VEGF ,MMP-9 and TIMP-1 before and after treatment in invalid group ( P >0.05).Conclusion The expression levels of serum MMP-9 and TIMP-1 may be correlated to the therapeutic effect of gefitinib on NSCLC ,whch suggests that MMP-9 and TIMP-1 may reflect the changes of patient ’ s condition and may be helpful for predicting the progress of NSCLC and prognosis of patients .
Keywords：non small cell lung carcinomagefitinibVEGFMMP-9TIMP-1
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 2416-2418 )